Bayer Investor News | Bayer Global

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

1 - 10of 456 News

1 - 10of 456 News

January 30, 2026

Not intended for U.S. and UK Media

Finerenone recommended for the treatment of patients with heart failure with LVEF ≥40% in the EU

January 16, 2026

Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation

January 16, 2026

Not intended for U.S. and UK Media

Eylea™ 8 mg approved in the EU for third retinal indication

January 06, 2026

Not intended for U.S. and UK Media

Bayer receives Breakthrough Therapy Designation in the U.S. and China for sevabertinib as a first-line treatment for patients with HER2-mutant non-small cell lung cancer

December 22, 2025

Not intended for U.S. and UK Media

Finerenone approved in Japan for treatment of patients with chronic heart failure

December 12, 2025

Not intended for U.S. and UK Media

Aflibercept 8 mg recommended for EU approval for third retinal indication

December 02, 2025

Bayer welcomes Solicitor General support for U.S. Supreme Court review

November 23, 2025

Bayer’s FXIa inhibitor Met Primary Efficacy and Safety Endpoints in Landmark Phase III Study in Secondary Stroke Prevention

November 20, 2025

Not intended for U.S. and UK Media

Accelerated approval in the U.S. for new treatment for patients with previously treated advanced HER2-mutant non-small cell lung cancer

November 19, 2025

EU approval for new hormone-free treatment option for vasomotor symptoms associated with menopause or caused by endocrine therapy for breast cancer

Inform Yourself on Special Topics

Control Weeds Not Farming

Control Weeds, Not Farming

Farmers discussing their weed management

Everything You Need to Know About Glyphosate

some-bayer-group-headquarters

Managing Glyphosate Litigation

woman harvesting carrots

Managing and Mitigating PCB Litigation Risk